Discover and read the best of Twitter Threads about #ADA2021
Most recents (4)
Yes it's the @GoggleDocs as we continue our #takeover of the @cardiomet_CE account.
Reporting some of the things that interested us in the recent #EASD2021
Please check out our previous mini-tweetorials.
@EASDnews @EASDelearning @ADA_DiabetesPro
Reporting some of the things that interested us in the recent #EASD2021
Please check out our previous mini-tweetorials.
@EASDnews @EASDelearning @ADA_DiabetesPro
Thus far we have covered...
▶️ Latest data on tirzepatide (GIP/GLP-1 dual agonist)✅
▶️ "Triple G" - a new GIP/GLP-1/Glucagon agonist✅
▶️ Remission in non-obese #type2diabetes ✅
Next up is "what's next after metformin?" - what the GRADE & TriMaster Studies add
▶️ Latest data on tirzepatide (GIP/GLP-1 dual agonist)✅
▶️ "Triple G" - a new GIP/GLP-1/Glucagon agonist✅
▶️ Remission in non-obese #type2diabetes ✅
Next up is "what's next after metformin?" - what the GRADE & TriMaster Studies add
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
📍Presented an update at the #EASD2021 , although little changed from the #ADA2021 presentation.
Please check out one of our own @GoggleDocs posts at the time
📍Presented an update at the #EASD2021 , although little changed from the #ADA2021 presentation.
Please check out one of our own @GoggleDocs posts at the time
1/6
#ADA2021
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Q. What next after metformin?
MET plus:
✅GLP-1ra (liraglutide)
✅Insulin(glargine)
✅SU (glimepiride)
✅DPP4i (sitagliptin)
But
😱 No SGLT2i
😱 No TZD
care.diabetesjournals.org/content/36/8/2…
#ADA2021
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Q. What next after metformin?
MET plus:
✅GLP-1ra (liraglutide)
✅Insulin(glargine)
✅SU (glimepiride)
✅DPP4i (sitagliptin)
But
😱 No SGLT2i
😱 No TZD
care.diabetesjournals.org/content/36/8/2…
2/6
Mean baseline characteristics
57 yr old
♀️36%
66%👴🏻, 20%👴🏿
BMI 34
HbA1c 7.5%
Duration of diabetes 4.2 yr
⚠️🇺🇸 only study
⚠️only 3.6% from 'Asian' descent
⚠️ So not representative to non-🇺🇸 #type2diabetes
care.diabetesjournals.org/content/42/11/…
Mean baseline characteristics
57 yr old
♀️36%
66%👴🏻, 20%👴🏿
BMI 34
HbA1c 7.5%
Duration of diabetes 4.2 yr
⚠️🇺🇸 only study
⚠️only 3.6% from 'Asian' descent
⚠️ So not representative to non-🇺🇸 #type2diabetes
care.diabetesjournals.org/content/42/11/…
3/6
Summary of glycaemic outcomes
🥳GLP-1ra & Basal Insulin did best
💩DPP4i did worse. In particular if baseline HbA1c>7.8%
Bottom line - I don't think DPP-4i is a good option if HbA1c >7.8% (62mmol/mol)
📷courtesy of Prof. Matthews
Summary of glycaemic outcomes
🥳GLP-1ra & Basal Insulin did best
💩DPP4i did worse. In particular if baseline HbA1c>7.8%
Bottom line - I don't think DPP-4i is a good option if HbA1c >7.8% (62mmol/mol)
📷courtesy of Prof. Matthews
AMPLITUDE-O Trial
1/5
Cardiovascular outcome trial for Efpeglenatide an investigational once weekly Exendin-4 based GLP-1ra.
What are the unanswered questions
Do Exendin-based GLP-1a ⤵️ MACE❓
Do GLP-1ra ⤵️ MACE in people taking SGLT2i❓
Does GLP-1ra ⤵️ renal decline❓
#ADA2021
1/5
Cardiovascular outcome trial for Efpeglenatide an investigational once weekly Exendin-4 based GLP-1ra.
What are the unanswered questions
Do Exendin-based GLP-1a ⤵️ MACE❓
Do GLP-1ra ⤵️ MACE in people taking SGLT2i❓
Does GLP-1ra ⤵️ renal decline❓
#ADA2021
2/5
Main results
Efpeglenatide
⤵️3-point MACE by 27%
⤵️expanded MACE by 21%
⤵️Renal composite by 32%
⤵️MACE or non-CV death by 27%
Best data yet to suggest adding GLP-1ra to SGLT2i ⤵️MACE
@DLBHATTMD
Main results
Efpeglenatide
⤵️3-point MACE by 27%
⤵️expanded MACE by 21%
⤵️Renal composite by 32%
⤵️MACE or non-CV death by 27%
Best data yet to suggest adding GLP-1ra to SGLT2i ⤵️MACE
@DLBHATTMD
3/5
Renal outcomes
Efpeglenatide
⤵️Renal composite
⤵️Albuminuria
⤵️eGFR slope❗️
Renal outcomes
Efpeglenatide
⤵️Renal composite
⤵️Albuminuria
⤵️eGFR slope❗️
#ADA2021
1/6
✅Real world data from a 🇩🇪register of patients with ♂️#hypogonadism & #type2diabetes over 12 years!
❗️ ♂️ hypogonadism is common in T2D (≈ 50%)
⚠️@Bayer presented
⚠️ other data shown ⤴️ MACE
amjmed.com/article/S0002-…
So what did they find?
1/6
✅Real world data from a 🇩🇪register of patients with ♂️#hypogonadism & #type2diabetes over 12 years!
❗️ ♂️ hypogonadism is common in T2D (≈ 50%)
⚠️@Bayer presented
⚠️ other data shown ⤴️ MACE
amjmed.com/article/S0002-…
So what did they find?
2/6
Baseline Characteristics.
🤔As you can see two very different cohorts of patients.
⚠️ High risk of unresolved bias
Baseline Characteristics.
🤔As you can see two very different cohorts of patients.
⚠️ High risk of unresolved bias
3/6
Changes in testosterone and glycaemic markers over time.
Testosterone therapy assoc with
⤴️ Testosterone
⤵️ HbA1c
Changes in testosterone and glycaemic markers over time.
Testosterone therapy assoc with
⤴️ Testosterone
⤵️ HbA1c
